We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

137 hedge funds and large institutions have $1.87B invested in Clovis Oncology, Inc. in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 10

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

36% more call options, than puts

Call options by funds: $31.7M | Put options by funds: $23.3M

23% more capital invested

Capital invested by funds: $1.52B → $1.87B (+$356M)

22% more funds holding

Funds holding: 112137 (+25)

Holders
137
Holders Change
+25
Holders Change %
+22.32%
% of All Funds
3.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
36
Increased
64
Reduced
25
Closed
10
Calls
$31.7M
Puts
$23.3M
Net Calls
+$8.39M
Net Calls Change
+$13.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$352M +$25.5M +346,627 +7%
NMC
2
NEA Management Company
Maryland
$158M
Vanguard Group
3
Vanguard Group
Pennsylvania
$90.7M +$3.95M +53,818 +4%
VAM
4
Visium Asset Management
New York
$80.3M +$43.9M +598,439 +107%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$74.6M +$12.1M +165,171 +18%
PHS
6
PFM Health Sciences
California
$74.6M -$111M -1,506,688 -58%
BIT
7
BlackRock Institutional Trust
California
$65.4M +$22.1M +300,508 +47%
BFA
8
BlackRock Fund Advisors
California
$59.7M +$2.4M +32,653 +4%
O
9
OppenheimerFunds
New York
$58.9M +$62.5M +850,602 New
CPCM
10
Clifton Park Capital Management
Delaware
$54.8M
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$46.8M +$11.4M +155,635 +30%
Franklin Resources
12
Franklin Resources
California
$43.6M +$8.78M +119,600 +23%
State Street
13
State Street
Massachusetts
$36.9M -$2.47M -33,619 -6%
BBA
14
Baker Bros. Advisors
New York
$36.7M -$54.9K -748 -0.1%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$36M -$6.02M -82,028 -14%
RG
16
Redmile Group
California
$35.5M -$4.34M -59,072 -10%
SAM
17
Sectoral Asset Management
Quebec, Canada
$34.2M +$1.54M +21,000 +4%
BB
18
BB Biotech
Switzerland
$33.8M
HM
19
HealthCor Management
New York
$32.9M +$27.6M +376,437 +382%
SCA
20
SAC Capital Advisors
Connecticut
$31.7M -$52M -708,462 -61%
TCM
21
TimesSquare Capital Management
New York
$29.8M +$7.89M +107,450 +33%
QF
22
QVT Financial
New York
$27M -$668K -9,100 -2%
ACH
23
ArrowMark Colorado Holdings
Colorado
$18.7M -$3.04M -41,334 -13%
Northern Trust
24
Northern Trust
Illinois
$18.7M -$1.31M -17,812 -6%
JHIU
25
Janus Henderson Investors US
Colorado
$17.4M +$5.23M +71,260 +39%

CLVS Hedge Fund Activity: Q1 2014 in Review

137 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2014, worth a combined $1.87B — up 23% from $1.52B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CLVS positions and 10 closed out — a net gain of 26 holders — while 64 added to existing stakes and 25 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $62.5M. The largest seller was PFM Health Sciences, cutting an estimated $111M.

  • 137 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2014, up from 112 in Q4 2013.
  • Funds reported $1.87B of Clovis Oncology, Inc. stock for Q1 2014, up 23% quarter-over-quarter.
  • 36 funds opened new Clovis Oncology, Inc. positions in Q1 2014 and 10 closed out, a net change of +26 holders.
  • The largest Clovis Oncology, Inc. buyer in Q1 2014 was OppenheimerFunds, an estimated $62.5M added.
  • The largest Clovis Oncology, Inc. seller in Q1 2014 was PFM Health Sciences, an estimated $111M sold.

Based on aggregated 13F filings for Q1 2014.